Evaluation of Response to Induction-Chemotherapy in Correlation to p53 Genotype in NSCLC stage III; Phase II Study P53 analysis OP 3 cyles GEMZAR/ CIS.

Slides:

Advertisements

Similar presentations

Advertisements

Advances and Emerging Therapy for Lung Cancer

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.

Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

C.P. Belani 1, T. Brodowicz 2, P. Peterson 3, W. John 3, G. Scagliotti 4 1 Penn State Cancer Institute, Hershey, PA USA; 2 Medical University, Vienna,

H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.

SARC023 Phase I/II trial of ganetespib, an heat shock protein 90 inhibitor in combination with the mTOR inhibitor sirolimus for patients with unresectable.

Modified Megestrol The Clinical Trials by : Carolina R. Akib

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

Breast Cancer By: Vincent Russo And Scott Jeffery.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Luveris ® New Drug Application ( ) Kate Meaker, M.S. Statistical Reviewer Division of Biometrics II Kate Meaker, M.S. Statistical Reviewer Division.

Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.

1 Non–Small-Cell Lung Cancer Diagnosis and Staging EvaluationPurpose Physical examinationIdentify signs Chest x-rayDetermine position, size, number of.

ACRIN 6678 Site Training ACRIN 6678 FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung.

SARC 005: Adjuvant treatment of high risk uterine LMS with gemcitabine/docetaxel followed by doxorubicin: a phase II multi-center trial PI: Martee.

ACRIN 6678 Site Training ACRIN 6678 FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung.

INT Translational research in head and neck cancer: preoperative chemotherapy in oral cavity cancer based on disease molecular profiling. Paolo Bossi MSO.

Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.

Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy

Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Grace Thacker Xavier University of Louisiana LSUHC – Internal Medicine

SARC 005: Adjuvant treatment of high risk uterine LMS with gemcitabine/docetaxel followed by doxorubicin: a phase II multi- center trial PI: Martee L.

P53 adapted neoadjuvant therapy for esophageal cancer: Pilot study Gastrointestinal (Non colorectal) cancer Poster discussion session Sat, June 2, 2007.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR SECOND LINE THERAPY OF SQUAMOUS CELL LUNG CANCER. (LUNG-MAP) THIS SLIDE DECK CONTAINS AN OVERVIEW OF.

Adjuvant therapy: LMS High activity of gemcitabine/docetaxel in advance disease suggests potential role as adjuvant therapy Adjuvant phase II study of.

Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

R2 김재민 / Prof. 정재헌 Journal conference 1.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

ADJUVANT CAPECITABINE AND OXALIPLATIN FOR GASTRIC CANCER AFTER D2 GASTRECTOMY (CLASSIC): A PHASE 3 OPEN-LABEL,RANDOMISED CONTROLLED TRIAL Yung-Jue Bang*,

Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.

R2 김형오 / Pf. 김시영.  Recent results  Presence of extensive lymphocytic infiltration in early stage breast cancer  Good prognosis  High response rates.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.

Randomized Phase III Study Of Gemcitabine

The Uganda Cancer Institute Experience Walusansa Victoria.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Alessandra Gennari, MD PhD

Delivery of systemic therapy in Gloucestershire for NSCLC

TERAPIA SEQUENZIALE E/O DI MANTENIMENTO DOPO UNA PRIMA LINEA: ANCORA UN TRATTAMENTO SPERIMENTALE? Paolo Bidoli S.C. Oncologia Medica A.O. San Gerardo Monza.

Fondazione IRCCS Istituto Nazionale Tumori

ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.

Prognosis of younger patients in non-small cell lung cancer

Clinical Research Management

Clinical Research Management

Clinical Research Management

Clinical Research Management

Clinical Research Management

Intervista a Lucio Crinò

Acquired EGFR TKI resistance: What are the current therapeutic strategies? Gregory J. Riely.

What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases? Systemic chemotherapy->chemoradiation->surgery.

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

What’s new in stage III lung cancer?

MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)

Trends in survival from metastatic lung cancer in California,

Treatment of Stage III Non-small Cell Lung Cancer

Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Presentation transcript:

Evaluation of Response to Induction-Chemotherapy in Correlation to p53 Genotype in NSCLC stage III; Phase II Study P53 analysis OP 3 cyles GEMZAR/ CIS Response DG P53 analysis 3 cycles DOCETAXEL mono P53 analysis Failure OP Purpose: First prospective evaluation of the impact of the p53 genotype for response to different CTs

Evaluation of response to induction - CT in correlation to p53 genotype in NSCLC stage III ; phase II study Short title: p53 tailored induction therapy Currently open, accademical study 7 investigational centers in Austria 25 patients accrued, 37 additional needed Intended by www.p53.at

Evaluation of response to induction-CT in correlation to p53 genotype in NSCLC stage III; phase II study Inclusion NSCLC Stage IIIA or IIIB No prior NSCLC therapy Age 18-70 Exclusion Recent CT with investigational drug Second primary CA Concurrent other tumor therapy